Capricor Therapeutics Reports Strong Phase 3 Data for Deramiocel, Secures $265M in Financing, and Confirms August 2026 PDUFA Date

summarizeSummary

Capricor Therapeutics filed its annual 10-K, detailing positive Phase 3 HOPE-3 clinical trial results for Deramiocel in Duchenne muscular dystrophy, a successful $265 million capital raise, and a confirmed FDA PDUFA date of August 22, 2026, for potential approval.

check_boxKey Events

• Positive Phase 3 HOPE-3 Clinical Trial Results

  The company announced positive topline results from the Phase 3 HOPE-3 study for Deramiocel in Duchenne muscular dystrophy, showing statistical significance in the primary endpoint (PUL v2.0) and key secondary cardiac endpoint (Left Ventricular Ejection Fraction). Additional analyses presented in March 2026 demonstrated a statistically significant reduction in myocardial fibrosis and an overall treatment effect favoring Deramiocel.

• Deramiocel BLA Resubmission Accepted by FDA

  The FDA accepted the Biologics License Application (BLA) resubmission for Deramiocel as a Class 2 response, assigning a new Prescription Drug User Fee Act (PDUFA) target action date of August 22, 2026, for potential approval in the United States. This follows a Complete Response Letter (CRL) received in July 2025.

• Strengthened Financial Position with $265M Capital Raise

  Capricor Therapeutics significantly boosted its liquidity, reporting approximately $318.1 million in cash, cash equivalents, and marketable securities as of December 31, 2025. This increase was driven by a December 2025 underwritten public offering that generated $172.5 million, sales of $77.5 million under an At-The-Market (ATM) program, and a $15.0 million private placement with Nippon Shinyaku.

• Increased Operating Losses and Cash Burn

  The company reported a net loss of approximately $105.0 million for the year ended December 31, 2025, a significant increase from $40.5 million in 2024. Cash used in operating activities also increased to $69.8 million in 2025 from $40.0 million in 2024, reflecting substantial research and development expenditures.

auto_awesomeAnalysis

This annual 10-K filing provides comprehensive details on Capricor Therapeutics' strong clinical progress and significantly improved financial runway. The positive Phase 3 HOPE-3 trial results for Deramiocel, including statistically significant improvements in upper limb function, left ventricular ejection fraction, and reduction in myocardial fibrosis, are critical for its potential FDA approval. The FDA's acceptance of the BLA resubmission as a Class 2 with an August 22, 2026 PDUFA date sets a clear regulatory path. The company successfully raised approximately $265 million through public offerings, ATM sales, and a private placement, substantially increasing its cash position to $318.1 million. While operating losses and cash burn increased, these are expected for a clinical-stage biotech advancing a lead candidate towards commercialization. The disclosed legal proceedings introduce new risks, but no material accruals have been recorded yet. Overall, the filing signals significant de-risking of the lead asset and provides the necessary capital to pursue commercialization.